MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Interest Expense 2011-2026 | ALIM
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.2 M | 5.88 M | 5.41 M | 5.38 M | 4.87 M | 4.78 M | 5.58 M | 5.18 M | 4.69 M | 2.09 M | 533 K | 790 K | 1.12 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 533 K | 4.35 M |
Quarterly Interest Expense Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.15 M | 3.74 M | - | 1.69 M | 1.67 M | - | 1.5 M | 1.38 M | 1.36 M | - | 1.36 M | 1.35 M | 1.34 M | - | 1.28 M | 1.35 M | 1.29 M | - | 1.23 M | 1.24 M | 1.23 M | - | 1.21 M | 1.18 M | 1.15 M | - | 1.43 M | 1.38 M | 1.34 M | - | 1.33 M | 1.18 M | 1.34 M | - | 1.32 M | 1.15 M | 1.12 M | - | 408 K | 325 K | 129 K | - | 134 K | 129 K | 134 K | - | 187 K | 211 K | 234 K | - | 284 K | 284 K | 295 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.74 M | 129 K | 1.1 M |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
1.12 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.14 | -4.62 % | $ 123 M |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
606 K | $ 4.74 | 1.94 % | $ 66.6 M | USA |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
500 K | - | - | $ 36.6 M | USA |
 |
DURECT Corporation
DRRX
|
2.24 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
87.9 M | $ 11.08 | 0.82 % | $ 567 M | USA |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
127 K | $ 5.05 | -2.88 % | $ 313 M | USA |
 |
Harrow Health
HROW
|
21.3 M | $ 47.49 | -0.86 % | $ 1.55 B | USA |
 |
China Pharma Holdings
CPHI
|
27.4 K | $ 1.25 | - | $ 21.8 M |  China |
 |
Jupiter Wellness
JUPW
|
-5.37 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
-28 M | $ 6.75 | -3.3 % | $ 2.46 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.58 | -2.17 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
20 K | $ 3.64 | -3.96 % | $ 479 M | USA |
 |
Pacira BioSciences
PCRX
|
-373 K | $ 19.43 | 1.38 % | $ 899 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | $ 21.51 | 0.14 % | $ 2.05 B |  France |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
900 K | $ 15.06 | 0.2 % | $ 2.07 B | USA |
 |
ProPhase Labs
PRPH
|
764 K | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
2.3 M | $ 1.22 | 27.44 % | $ 28.5 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 3.33 | 1.06 % | $ 4.13 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 3.93 | 5.01 % | $ 118 M | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 12.04 | 4.88 % | $ 855 M | USA |
 |
Tilray
TLRY
|
46.6 M | $ 8.74 | -7.62 % | $ 5.4 B | Canada |
 |
Solid Biosciences
SLDB
|
652 K | $ 5.59 | 2.19 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 0.65 | -0.68 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
862 K | $ 2.53 | -5.95 % | $ 341 M | USA |
 |
TherapeuticsMD
TXMD
|
300 K | $ 2.55 | 14.39 % | $ 26.6 M | USA |
 |
Viatris
VTRS
|
592 M | $ 12.66 | -1.59 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
175 K | - | -0.21 % | $ 98 M | USA |
 |
cbdMD
YCBD
|
-29.5 K | $ 0.83 | -9.94 % | $ 3.58 M | USA |